ADA2 and deficiency of adenosine deaminase 2: A novel technology of gene transfer by lentiviral vector (LV)–mediated ADA2 gene correction has recently been proposed by preclinical investigations as a potential breakthrough in the treatment of DADA2 [23, 24].